|
B
i b l i o g r a f i a 1.
Sant
M. Barchetti A. Francisci S. e Canario F.: The prevalence of tumor of
the breast and female genital tract in Italy.
Tumori
85/1999: 382-389 2. Early Breast Cancer Trialists' Collaborative Group:
Systemic treatment of Breast Cancer by hormonal, cytotoxic or immune
therapy.
Lancet
339/8785:1-15,71-85 3. Polychemotherapy of early Breast Cancer: an overview
of the randomized trials. Early Breast Cancer Trialists' Collaborative
Group.
Lancet
352/9132: 19,352, 1998 4. Fisher H. Anderson S. Wickerman D. et al Increased
intensification and total dose of Cyclophosfamide in a doxorubicin-cyclophosfamide
sequence for the treatment of primary Breast Cancer.
Findings of National Surgical Adjuvant Breast and Bowel project B12.
J.Clin.Onc. 1997 15(5) 1958-1869. 5. Swain S. Adjuvant chemotherapy
for all.
Program
and Abstracts of the 10th International Congress of Anti-Cancer Treatment,
Paris January 31- February 3, Educational lectures 012 6. Tamoxifen
for early Breast Cancer: an overview of the randomized trials. Lancet
351 ( 9114): 1451-1467, 1998. 7. Piccart MS. Lohrisch C. Straehle C.
New strategies in the treatment of non-metastatic breast cancer.
Program and Abstracts of the 10th Intemational Congress of Anti-Cancer
Treatment, Paris January 31- February 3, Educational lectures 024. 8.
Hutchins L. Green S. Radvin P et al.
CMF
versus CAF+Tamoxifen in high risk node negative Breast Cancer patients
and natural history Follow up study in low risk node negative patients.
Program and Abstracts of the 22nd Annual San Antonio Breast Cancer Symposium,
December 8-11, 1999 San Antonio Tx, abs 1 9. Harbeck N Alt U Thomssen
C et al Long term Follow up confirms prognostic impact of PAI-1 and
Cathepsin D and L in primary Breast Cancer. Program and Abstracts of
the 22nd Annual San Antonio Breast Cancer Symposium, December 8-11,
1999 San Antonio Tx, abs 402 10. Chong D Cooke TG Reeves J et al Quantitation
of c-erbB-2 in primary Breast Cancer allows identification of a further
poor prognostic group Program and Abstracts of the 22nd Annua1 San Antonio
Breast Cancer Symposium, December 8-11, 1999 San Antonio Tx, abs 422.
11. Espinoza F Anguiano A Samoszuk MK. Rate of HER2 overexpression as
measured by Hercep Test tm assay and FISH. Program and Abstracts of
the 22nd Annual San Antonio Breast cancer Symposium, December 8-11,
1999 San Antonio Tx, abs 228
Back
Indietro
|
